PRECLINICAL EVALUATION OF PRODRUG ACTIVATOR GENE THERAPY BY RETROVIRAL REPLICATING VECTORS (RRV) IN HUMAN AND MOUSE GLIOMA MODELS

被引：0
|
作者：
Hiraoka, Kei [1 ]
Inagaki, Akihito [1 ]
Logg, Christopher R. [1 ]
Kamijima, Shuichi [1 ]
Ostertag, Derek [2 ]
Perez, Omar D. [2 ]
Gruber, Harry E. [2 ]
Jolly, Douglas J. [2 ]
Robbins, Joan M. [2 ]
Kasahara, Noriyuki [1 ]
机构：
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[2] Tocagen Inc, San Diego, CA USA
来源：
JOURNAL OF GENE MEDICINE | 2014年 / 16卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
OR-87
引用
收藏
页码：264 / 265
页数：2
相关论文
共 50 条
  • [1] Preclinical Evaluation of Prodrug Activator Gene Therapy by Retroviral Replicating Vectors (RRV) in Experimental Models of Breast Cancer CNS Metastasis
    Inagaki, Akihito
    Hiraoka, Kei
    Kamijima, Shuichi
    Robbins, Joan M.
    Jolly, Douglas J.
    Gruber, Harry E.
    Kasahara, Noriyuki
    MOLECULAR THERAPY, 2015, 23 : S250 - S250
  • [2] Sequence-Optimized Nitroreductase for Retroviral Replicating Vector (RRV) Mediated Prodrug Activator Gene Therapy in Human Glioma Models
    Collins, Sara A.
    Logg, Christopher R.
    Inagaki, Akihito
    Kamijima, Shuichi
    Lehouritis, Panos
    Searle, Peter F.
    Tangney, Mark
    Kasahara, Noriyuki
    MOLECULAR THERAPY, 2015, 23 : S171 - S171
  • [3] RETROVIRAL REPLICATING VECTORS PSEUDOTYPED WITH GIBBON APE LEUKEMIA VIRUS ENVELOPE FOR PRODRUG ACTIVATOR GENE THERAPY IN PRECLINICAL GLIOMA MODELS
    Inagaki, Akihito
    Collins, Sara
    Freedman, Alicia
    Montoya, Megan
    Haddad, Alexander
    Barcova, Maria
    Kasahara, Noriyuki
    NEURO-ONCOLOGY, 2021, 23 : 170 - 170
  • [4] Development of Sequence-Optimized Nitroreductase for Retroviral Replicating Vector (RRV)-Mediated Prodrug Activator Gene Therapy in Human Glioma Models
    Collins, Sara A.
    Inagaki, Akihito Inagaki
    Tai, Chien-Kuo
    Logg, Christopher R.
    Searle, Peter F.
    Tangney, Mark
    Kasahara, Noriyuki
    MOLECULAR THERAPY, 2020, 28 (04) : 157 - 157
  • [5] leDEVELOPMENT OF RETROVIRAL REPLICATING VECTORS ENCODING SEQUENCE-OPTIMIZED NITROREDUCTASE FOR PRODRUG ACTIVATOR GENE THERAPY IN HUMAN GLIOMA MODELS
    Collins, Sara
    Inagaki, Akihito
    Tai, Chien-Kuo
    Logg, Christopher R.
    Searle, Peter
    Tangney, Mark
    Kasahara, Noriyuki
    NEURO-ONCOLOGY, 2020, 22 : 96 - 96
  • [6] RETROVIRAL REPLICATING VECTOR (RRV)-MEDIATED PRODRUG ACTIVATOR GENE THERAPY WITH CODON-OPTIMIZED NITROREDUCTASE IN EXPERIMENTAL GLIOMA
    Collins, Sara
    Logg, Christopher
    Inagaki, Akihito
    Kamijima, Shuichi
    Lehouritis, Panos
    Searle, Peter
    Tangney, Mark
    Kasahara, Noriyuki
    NEURO-ONCOLOGY, 2014, 16
  • [7] Dual Prodrug Activator Gene Therapy with Pseudotyped Retroviral Replicating Vectors
    Grosso, James
    Collins, Sara
    Inagaki, Akihito
    Kamath, Priyanka
    Slomovitz, Brian
    Kasahara, Noriyuki
    MOLECULAR THERAPY, 2018, 26 (05) : 210 - 210
  • [8] Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors in an Experimental Model of Human Osteosarcoma
    Kubo, Shuji
    Takagi-Kimura, Misato
    Kasahara, Noriyuki
    MOLECULAR THERAPY, 2017, 25 (05) : 61 - 61
  • [9] Improved Retroviral Replicating Vectors for Prodrug-Activator Gene Therapy of Cancer
    Kirk, Kaitlyn
    Hao, Ergeng
    Martinson, Laura
    Kroon, Evert
    Itkin-Ansari, Pamela
    MOLECULAR THERAPY, 2011, 19 (07) : 1361 - 1362
  • [10] Retroviral Replicating Vector (RRV)-Mediated Prodrug Activator Gene Therapy With Codon-Optimized Nitroreductase
    Collins, S. A.
    Logg, C. R.
    Inagaki, A.
    Hiraoka, K.
    Kamijima, S.
    Herman, K.
    Searle, P. F.
    Tangney, M.
    Kasahara, N.
    HUMAN GENE THERAPY, 2012, 23 (10) : A92 - A92
12345